Oxford Innovation EIS Growth Fund alongside OION angel investors, has made a follow-on investment in orthopaedics company OSSTEC, further supporting its mission to revolutionise bone healing implants. OSSTEC’s proprietary biomimetic platform technology, developed over eight years of research at Imperial College London, is setting new standards in orthopaedic innovation. Unlike traditional implants, its fully porous 3D-printed implants stimulate long-term bone growth, significantly reducing the risks of implant loosening and bone loss.
Since its inception OSSTEC has raised a total of £4.5 million, accelerating its progress towards transforming knee implant technology. Following Oxford Innovation’s previous investment in March 2023, the company has reached several significant milestones, further advancing its innovation and market position:Regulatory Progress – advancing its pathway toward regulatory approval, paving the way for the first in-human clinical procedures.Expanded Research & Development – after unveiling its first product in 2023, OSSTEC has strengthened its R&D capabilities, further enhancing the efficacy and precision of its 3D printing technology.Industry Collaborations – forming strategic partnerships with leading orthopaedic surgeons and institutions to refine implant performance and clinical adoption.
Market Expansion – engaging with international stakeholders to position OSSTEC as a global leader in next-generation orthopaedic implants.The knee implant market is expected to reach over $12 billion by 2027, driven by an aging population and rising cases of osteoarthritis. Current studies indicate that up to 20% of knee replacement patients experience chronic pain or complications, often linked to implant loosening and failure. OSSTEC’s fully porous implants offer a breakthrough solution to this challenge, delivering a more natural, long-lasting integration with the patient’s bone structure.
Dr Max Munford, co-founder and Chief Executive of OSSTEC said:
“The demand for better-performing knee implants is higher than ever. With 1.3 million knee replacement procedures performed annually worldwide, and a growing need for solutions suited to younger, more active patients, OSSTEC is at the forefront of change. With the support of this latest investment, our technology can improve patient outcomes by ensuring superior bone integration, ultimately extending the lifespan of implants and reducing the need for revision surgeries.”
This latest investment underscores Oxford Innovation Finance’s commitment to fostering high-growth UK science and technology ventures, ensuring that groundbreaking technologies like OSSTEC’s move from the lab to the operating room, ultimately benefiting patients globally.
Richard Cooper, Managing Director at Oxford Innovation Finance, commented:
“OSSTEC continues to exceed expectations on its journey to bring cutting-edge 3D-printed orthopaedic implants to market. Their innovative approach is addressing a critical need in the medical industry, and we are proud to continue supporting their growth. We believe OSSTEC has the potential to significantly improve the standard of care for knee replacement patients worldwide.”
Published: April 2025.